The present study indicated that FZKA may inhibit lung cancer metastasis via the STAT3/MMP9 pathway and EMT, suggesting that FZKA may serve as a novel promising therapeutic strategy for the treatment of patients with late stage lung cancer.
Countstar Connection
Researchers assessed cell numbers in the study's cell samples using Countstar (model not specified) during quality assessment for the cancer-model experiments.
